{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:40:14Z","timestamp":1756363214960,"version":"3.44.0"},"reference-count":9,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,4,17]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>A woman in her 30s presented to the dermatology clinic with widespread, pruritic, red papules and plaques involving the ears, trunk and extremities. The rash developed a few days after receiving her second injection of secukinumab, which was initiated for recalcitrant Hurley stage III hidradenitis suppurativa. Investigations revealed a psoriasiform drug hypersensitivity reaction secondary to secukinumab. In this report, we describe the clinical course, histopathological correlation and treatment of this rarely documented reaction.<\/jats:p>","DOI":"10.1136\/bcr-2022-249684","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T13:45:16Z","timestamp":1653313516000},"page":"e249684","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa"],"prefix":"10.1136","volume":"15","author":[{"given":"Sasank","family":"Konda","sequence":"first","affiliation":[{"name":"Dermatology, Henry Ford Hospital, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8309-2654","authenticated-orcid":false,"given":"Nayha","family":"Shetty","sequence":"additional","affiliation":[{"name":"Dermatology, Henry Ford Hospital, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Friedman","sequence":"additional","affiliation":[{"name":"Dermatology, Henry Ford Hospital, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Veenstra","sequence":"additional","affiliation":[{"name":"Dermatology, Henry Ford Hospital, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"2025082722591893000_15.5.e249684.1","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025082722591893000_15.5.e249684.2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40629-020-00126-6","article-title":"Hypersensitivity reactions to biologics (part\u00a0I): allergy as an important differential diagnosis in complex immune-derived adverse events","volume":"29","author":"G\u00fclsen","year":"2020","journal-title":"Allergo J Int"},{"key":"2025082722591893000_15.5.e249684.3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1684\/ejd.2016.2900","article-title":"Drug eruption caused by secukinumab","volume":"27","author":"Shibata","year":"2017","journal-title":"Eur J Dermatol"},{"key":"2025082722591893000_15.5.e249684.4","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1111\/jdv.14248","article-title":"Adverse skin reaction to Secukinumab","volume":"31","author":"Peigottu","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082722591893000_15.5.e249684.5","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1097\/RHU.0000000000001065","article-title":"Secukinumab-induced delayed-type drug hypersensitivity reactions","volume":"26","author":"Wong","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"2025082722591893000_15.5.e249684.6","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1016\/j.jaip.2020.06.016","article-title":"Delayed-type hypersensitivity to secukinumab with tolerance to ixekizumab","volume":"8","author":"Darrigade","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025082722591893000_15.5.e249684.7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/jamadermatol.2017.2826","article-title":"Secukinumab-induced psoriasiform eruption","volume":"153","author":"Sladden","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2025082722591893000_15.5.e249684.8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ced.13731","article-title":"Secukinumab-induced paradoxical pustular psoriasis","volume":"44","author":"Dogra","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"2025082722591893000_15.5.e249684.9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/19420862.2015.1136761","article-title":"Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity","volume":"8","author":"Karle","year":"2016","journal-title":"MAbs"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-249684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:59:31Z","timestamp":1756360771000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-249684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":9,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,17]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/bcr-2022-249684"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-249684","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}